MedPath

A randomized controlled trial of cognitive behavior therapy as an adjunct to usualcare for social anxiety disorder refractory to initial SSRI treatment

Not Applicable
Conditions
Social Anxiety Disorder, Social Phobia
Registration Number
JPRN-UMIN000007552
Lead Sponsor
Research Center for Child Mental Development, Department of Cognitive Behavioral Physiology, Graduate School of Medicine, Chiba University
Brief Summary

This study aimed to examine the effectiveness of cognitive behavioral therapy (CBT) as an adjunct to usual care (UC) when compared to UC alone in SAD patients who remain symptomatic following antidepressant treatment. Patients were randomly allocated to CBT + UC (n=21) or UC-alone (n=21) group. After 16 weeks, the mean reduction in the Liebowitz Social Anxiety Scale from baseline for CBT + UC and UC-alone was -40.87 and 0.68, respectively; between-group difference was -41.55 (-53.68 to -29.42, p<0.0001). Response rates were 85.7% and 10.0% for CBT + UC and UC-alone, respectively (p<0.0001); the corresponding remission rates were 47.6% and 0.0%, respectively (p=0.0005). Significant differences were also found in favor of CBT + UC for social anxiety symptoms, depressive symptoms, and functional impairment. Our results suggest that in SAD patients who have been ineffectively-treated with antidepressant, CBT is an effective treatment adjunct to UC over 16 weeks in reducing social anxiety and related symptoms.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
42
Inclusion Criteria

Not provided

Exclusion Criteria

psychosis, major depression, bipolar, active suicidality, organic brain disorder, substance abuse or dependence, antisocial personality disorder, other severe mental / physical condition

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath